Pathogenesis and treatment of postmenopausal osteoporosis

Milhaud, G; Christiansen, Claus; Gallagher, C.; Reeve, J.; Seeman, Ego; Chesnut, Charles H.; Parfitt, A. M.

doi:10.1007/bf02405109

Cited by 8 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age-related bone loss is an inescapable condition of humanity, affecting all groups studied, whether defined by sex, race, economic development, geographic location, or historical epoch [91]. In normal individuals, peak bone mass is reached at age 25 -35 years and after that a decrease with age occurs in both sexes [85].…”

Section: Introductionmentioning

confidence: 99%

Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities

Steiniche

1995

APMIS

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities

Steiniche

1995

APMIS

View full text Add to dashboard Cite

“…The physiologic decline of estrogens in women begins from 1 to 2 years before menopause and reaches its plateau about 1 to 2 years after the menses cessation. 12 The drop in estrogens explains the quick rise in the rate of bone resorption and therefore of bone loss, with an increase of the risk of osteoporosis. 13 In young women in whom premature menopause is induced by surgery or cancer treatments, the estrogen drop can be particularly marked and its adverse effects (AEs) on bone loss and fracture risk are therefore greater.…”

Section: Hormonal Therapymentioning

confidence: 99%

Pharmacological Management of Osteoporosis in Postmenopausal Women: The Current State of the Art

Gatti

Fassio

2019

jptcp

View full text Add to dashboard Cite

Osteoporosis is a common disease that increases fracture risk. Fragility fractures bring heavy consequences in terms of mortality and disability, with burdensome health and social costs. In subjects with clinical bone fragility, the first goal is to identify the secondary forms of osteoporosis, especially in young subjects, in males and in patients who recently experienced a fragility fracture. In addition, before considering any sort of treatment, it is fundamental to check for adequate calcium and vitamin D intake, since their deficiency is the most common reason for drug failure. In the last decade of the 20th century, several molecules have been developed and proved to be effective in achieving the true goal of any antiosteoporotic drug: fracture prevention. In this article, we considered the most commonly prescribed antiresorptive drugs (hormonal therapy, bisphosphonates, and denosumab), the anabolic agents (teriparatide), the dual-action drugs (romosozumab), and the drugs characterized by an unclear mechanism of action (strontium ranelate) to provide physicians with useful insights for their clinical practice. We discussed the main criteria for the appropriate choice selection and management of each treatment. Finally, we addressed the current controversies related to treatment discontinuation, sequential, and combination therapy.

show abstract

“…However there are few who would now deny the relationship between physical activity and bone mass; but agreement on the effect of other drugs used in osteoporosis is as far away as ever (Milhaud et al, 1983). Oral calcium is cheap, safe and undistinguished, but recent work (Riggs et al, 1982) suggests that it is better than nothing.…”

Section: Management Of Osteoporosismentioning

confidence: 99%

Osteoporosis—a problem of bone formation?

Smith

1984

Postgraduate Medical Journal

View full text Add to dashboard Cite

Pathogenesis and treatment of postmenopausal osteoporosis

Cited by 8 publications

References 4 publications

Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities

Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities

Pharmacological Management of Osteoporosis in Postmenopausal Women: The Current State of the Art

Osteoporosis—a problem of bone formation?

Contact Info

Product

Resources

About